Drs. Schanberg and Sandborg contributed equally to this work.
Use of atorvastatin in systemic lupus erythematosus in children and adolescents†
Version of Record online: 29 DEC 2011
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 1, pages 285–296, January 2012
How to Cite
Schanberg, L. E., Sandborg, C., Barnhart, H. X., Ardoin, S. P., Yow, E., Evans, G. W., Mieszkalski, K. L., Ilowite, N. T., Eberhard, A., Imundo, L. F., Kimura, Y., von Scheven, E., Silverman, E., Bowyer, S. L., Punaro, M., Singer, N. G., Sherry, D. D., McCurdy, D., Klein-Gitelman, M., Wallace, C., Silver, R., Wagner-Weiner, L., Higgins, G. C., Brunner, H. I., Jung, L., Soep, J. B., Reed, A. M., Provenzale, J., Thompson, S. D. and Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators (2012), Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis & Rheumatism, 64: 285–296. doi: 10.1002/art.30645
ClinicalTrials.gov identifier: NCT00065806.
- Issue online: 29 DEC 2011
- Version of Record online: 29 DEC 2011
- Accepted manuscript online: 26 OCT 2011 03:08PM EST
- Manuscript Accepted: 18 AUG 2011
- Manuscript Received: 8 FEB 2011
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Grant Number: N01-AR-2-2265
- Edna and Fred L. Mandel Jr. Center for Hypertension and Atherosclerosis
- NIH (Clinical and Translational Science Award program). Grant Number: UL1-RR-024989
Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy and safety in children and adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine the 3-year efficacy and safety of atorvastatin in preventing subclinical atherosclerosis progression in pediatric-onset SLE.
A total of 221 participants with pediatric SLE (ages 10–21 years) from 21 North American sites were enrolled in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus study, a randomized double-blind, placebo-controlled clinical trial, between August 2003 and November 2006 with 36-month followup. Participants were randomized to receive atorvastatin (n = 113) or placebo (n = 108) at 10 or 20 mg/day depending on weight, in addition to usual care. The primary end point was progression of mean-mean common carotid intima-media thickening (CIMT) measured by ultrasound. Secondary end points included other segment/wall-specific CIMT measures, lipid profile, high-sensitivity C-reactive protein (hsCRP) level, and SLE disease activity and damage outcomes.
Progression of mean-mean common CIMT did not differ significantly between treatment groups (0.0010 mm/year for atorvastatin versus 0.0024 mm/year for placebo; P = 0.24). The atorvastatin group achieved lower hsCRP (P = 0.04), total cholesterol (P < 0.001), and low-density lipoprotein (P < 0.001) levels compared with placebo. In the placebo group, CIMT progressed significantly across all CIMT outcomes (0.0023–0.0144 mm/year; P < 0.05). Serious adverse events and critical safety measures did not differ between groups.
Our results indicate that routine statin use over 3 years has no significant effect on subclinical atherosclerosis progression in young SLE patients; however, further analyses may suggest subgroups that would benefit from targeted statin therapy. Atorvastatin was well tolerated without safety concerns.